Trial Profile
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Jun 2021 Status changed from not yet recruiting to completed.
- 04 Jan 2018 New trial record